Literature DB >> 33902076

Concurrent Longitudinally Extensive Transverse Myelitis and Guillain-Barré Syndrome in a Child Secondary to COVID-19 Infection: A Severe Neuroimmunologic Complication of COVID-19.

Daisy Khera1, Siyaram Didel, Samhita Panda, Sarbesh Tiwari, Kuldeep Singh.   

Abstract

Neurologic manifestation of coronavirus disease 2019 (COVID-19) in children is evolving with time. We are reporting a young girl who presented to us with acute febrile illness followed by acute onset severe flaccid paralysis requiring prolonged intensive care unit stay and ventilator support. She was evaluated extensively and found to be positive for COVID serology, and neuroimaging revealed features of longitudinally extensive transverse myelitis (LETM) with enhancing cauda equina nerve roots, suggesting Guillain-Barré Syndrome (GBS). She failed to respond to immune suppressive therapy and needed plasma exchange for recovery. Like other common viral illnesses, COVID-19 can also act as a trigger for GBS-like illness and LETM, and we need to suspect these diagnoses in the cases with COVID-19 infection in compatible cases. This is probably the first pediatric case with concurrent GBS and LETM secondary to COVID-19 infection.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33902076     DOI: 10.1097/INF.0000000000003124

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Acute Ascending Necrotizing Myelitis After COVID-19 Infection: A Clinicopathologic Report.

Authors:  Luis Guada; Franklyn Rocha Cabrero; Nicole L Baldwin; Allan D Levi; Sakir H Gultekin; Ashok Verma
Journal:  Neurol Clin Pract       Date:  2022-06

2.  COVID-19 and MOG-IgG-associated acquired demyelinating polyneuropathy compatible with chronic inflammatory demyelinating polyneuropathy in a previously healthy girl.

Authors:  Asra Akbar; Gregory M Blume; Sean Creeden; Sharjeel Ahmad
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-06-17

Review 3.  Spectrum of neuroimaging mimics in children with COVID-19 infection.

Authors:  Alex Mun-Ching Wong; Cheng Hong Toh
Journal:  Biomed J       Date:  2021-11-15       Impact factor: 7.892

4.  A possible Guillain-Barré syndrome/transverse myelitis overlap syndrome after recent COVID-19.

Authors:  Riyadh Alrubaye; Vijayamala Bondugula; Vidya Baleguli; Rosemary Chofor
Journal:  BMJ Case Rep       Date:  2022-02-09

5.  Para and Post-COVID-19 CNS Acute Demyelinating Disorders in Children: A Case Series on Expanding the Spectrum of Clinical and Radiological Characteristics.

Authors:  Abdulhafeez M Khair; Rahul Nikam; Sumair Husain; Melanie Ortiz; Gurcharanjeet Kaur
Journal:  Cureus       Date:  2022-03-22

6.  Possible association between Guillain-Barré syndrome and SARS-CoV-2 infection in children: A case report and literature review.

Authors:  Ilaria Mussinatto; Chiara Benevenuta; Anna Caci; Mario M Calvo; Maria Impastato; Massimo Barra; Egidio Genovese; Fabio Timeus
Journal:  Exp Ther Med       Date:  2022-05-23       Impact factor: 2.751

Review 7.  An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review.

Authors:  Dan Li; Qiang Wang; Chengyou Jia; Zhongwei Lv; Jianshe Yang
Journal:  J Inflamm Res       Date:  2022-07-26

8.  Acute Hemorrhagic Myelitis in an Adolescent With COVID-19: A Case Report and Review of Literature.

Authors:  Yazid Maghrabi; Saleh S Baeesa
Journal:  Cureus       Date:  2021-12-20

9.  Guillain-Barre syndrome (GBS) associated with COVID-19 infection that resolved without treatment in a child.

Authors:  Samir Kanou; Lama Wardeh; Sandhya Govindarajan; Kayleigh Macnay
Journal:  BMJ Case Rep       Date:  2022-03-10

Review 10.  SARS-Cov-2 Damage on the Nervous System and Mental Health.

Authors:  Mohamed Said Boulkrane; Victoria Ilina; Roman Melchakov; Mikhail Arisov; Julia Fedotova; Lucia Gozzo; Filippo Drago; Weihong Lu; Alexey Sarapultsev; Vadim Tseilikman; Denis Baranenko
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.